lacosamide Side Effects
Also known as: Vimpat
Analysis of 35,350 adverse event reports submitted to the FDA from 2007 to 2025.
Total Reports
35,350
Death-Related
3,025
8.6% of reports
Hospitalizations
12,020
34.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 3,025 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 1,046 |
| OFF LABEL USE | 374 |
| DRUG INEFFECTIVE | 298 |
| SEIZURE | 253 |
| TOXICITY TO VARIOUS AGENTS | 177 |
| CARDIAC ARREST | 172 |
| STATUS EPILEPTICUS | 170 |
| COMPLETED SUICIDE | 150 |
| PNEUMONIA | 122 |
| CARDIO-RESPIRATORY ARREST | 109 |
| SUDDEN UNEXPLAINED DEATH IN EPILEPSY | 101 |
| MULTIPLE-DRUG RESISTANCE | 84 |
| OVERDOSE | 82 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 81 |
| EPILEPSY | 81 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 77 |
| SEPSIS | 77 |
| METABOLIC ACIDOSIS | 75 |
| FALL | 73 |
| PNEUMONIA ASPIRATION | 73 |
Reactions in Hospitalization Reports
Top reactions in 12,020 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| SEIZURE | 2,541 |
| DRUG INEFFECTIVE | 1,445 |
| OFF LABEL USE | 1,392 |
| STATUS EPILEPTICUS | 728 |
| FALL | 713 |
| EPILEPSY | 519 |
| HOSPITALISATION | 497 |
| OVERDOSE | 497 |
| SOMNOLENCE | 481 |
| DRUG INTERACTION | 466 |
| PNEUMONIA | 457 |
| VOMITING | 453 |
| DIZZINESS | 440 |
| GENERALISED TONIC-CLONIC SEIZURE | 420 |
| FATIGUE | 405 |
| CONVULSION | 393 |
| PYREXIA | 367 |
| TOXICITY TO VARIOUS AGENTS | 351 |
| HEADACHE | 342 |
| NAUSEA | 325 |
Nearby — Related Medications
What the FAERS Data Reveals About lacosamide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 35,350 voluntary reports linked to lacosamide and its brand equivalents (Vimpat), spanning 2007 through 2025. Of those, 3,025 (8.6%) listed death as an outcome and 12,020 (34.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 55% were female and 45% male; age distribution skews toward 18-44, with 7,367 reports in that bracket. The single most reported reaction is seizure with 6,507 submissions, followed by drug ineffective and off label use.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.